BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. is a leading global player in the genomics industry, dedicated to advancing gene technology for the benefit of humanity. Established in 2017 and listed on the ChiNext board of the Shenzhen Stock Exchange, BGI has developed a comprehensive marketing and service network that spans over 100 countries and all regions of China. The company focuses on integrating scientific research, talent development, and industrial growth within the genomics sector, positioning itself as a key technology provider across the entire industry chain. The core business of BGI includes offering research services, precision medical testing solutions, and health management services through advanced multi-omics and big data technologies. Its operations encompass various fields, including reproductive health, tumor prevention and control, chronic disease management, and infection prevention. BGI operates numerous genetic testing laboratories worldwide, collaborating with thousands of medical institutions and health authorities to deliver innovative solutions and improve healthcare standards. The company emphasizes research and development, holding numerous patents and trademarks, and is committed to enhancing the efficiency and quality of healthcare services through its technological advancements.

The company places high importance on innovation and technology R&D, maintaining substantial investment in upstream molecular testing technologies, information technology, and application fields such as reproductive health, tumor prevention and control, and infectious disease management. Over the years, this commitment has resulted in a series of significant patent achievements. As of June 30, 2025, the company and its wholly-owned and controlled subsidiaries held a total of 769 authorized patents, including 660 invention patents, 80 utility model patents, and 29 design patents. Additionally, the company owns 1,069 registered trademarks and has obtained 898 software copyrights for its independently developed software in areas such as bioinformatics analysis. The company is focused on industrializing two core products. One is the ChatGeneT platform, which leverages the independently developed GeneT multi-modal large model for genetic testing and the "Qingjian" expert knowledge base. By deeply exploring the layered relationships among genetic variations, clinical phenotypes, and clinical evidence, it forms an intelligent solution for genetic counseling scenarios. Equipped with capabilities such as precise multi-modal information integration, AI-powered analysis, and automated generation of consultation-enhancing dialogues, the platform has already established in-depth collaborations and joint R&D initiatives with several top-tier tertiary hospitals in China. These efforts aim to extend evidence-based genetic interpretation capabilities from high-level medical institutions to primary care settings, significantly improving outpatient consultation efficiency and medical service quality at all levels of hospitals, and supporting the high-quality, efficient development of the national tiered healthcare system. The company possesses strong expertise and extensive experience in constructing biological laboratories, including high-throughput sequencing labs and molecular laboratories. It is one of the world's largest medical genetic testing centers, operating 23 genetic testing laboratories across eight countries with a total area of approximately 40,000 square meters. These laboratories have cumulatively operated safely for over 4.22 million hours. As of June 30, 2025, the company has collaborated with thousands of medical institutions globally, establishing over 1,000 joint laboratories covering more than 100 countries and regions. The application of genetic sequencing technology in clinical settings—exemplified by non-invasive prenatal genetic testing, HPV genotyping, tumor genetic testing, and genetic disease testing—has gained widespread recognition. The company boasts comprehensive qualifications and advantages. As of June 30, 2025, 19 of its units hold Medical Institution Practice Licenses, and 17 medical testing laboratories have passed technical acceptance as clinical gene amplification testing laboratories. Key testing items, including single-gene genetic disease mutation detection, non-invasive prenatal testing for fetal chromosomal aneuploidy, low-depth whole-genome sequencing (CNV-seq), human papillomavirus (HPV) genotyping, and familial breast cancer gene mutation testing, have completed clinical gene amplification testing technology filings. Additionally, three medical testing laboratories are among the first pilot units approved for the clinical application of high-throughput gene sequencing technology in genetic disease diagnosis, preimplantation genetic diagnosis, and tumor diagnosis and treatment. The company has obtained 253 medical device registration certificates and filing certificates from the National Medical Products Administration (NMPA), along with 387 international medical device qualifications covering over 20 countries and regions, including the EU, Japan, Australia, Thailand, Saudi Arabia, Colombia, and Brazil, ensuring continuous compliance with market requirements in multiple jurisdictions. Furthermore, the company’s non-invasive prenatal genetic testing products have obtained 60 qualifications in regions such as the EU, Malaysia, Thailand, Saudi Arabia, the UK, India, Australia, Colombia, and the EAEU (Eurasian Economic Union), while its colorectal cancer testing products have received 63 qualifications in Brazil, Thailand, Saudi Arabia, Colombia, the UK, Australia, and other countries, facilitating global product promotion.